Clinical trials: End-Stage Kidney Disease (ESKD)
Kidney Failure, Chronic
VR-Guided Mindfulness for ESKD Caregiver Well-Being
This pilot randomized controlled trial aims to evaluate the efficacy and feasibility of a virtual reality (VR)-guided mindfulness intervention for caregivers of patients with end-stage kidney disease (ESKD).
- Trial name
- NCT06479200
- Testing
- VR-guided mindfulness
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Alexandra Hospital
End-Stage Kidney Disease (ESKD)
Pharmacokinetics of Oral Letermovir in Adults With End-Stage Kidney Disease With or Without Haemodialysis
This study aims to understand how the antiviral medication letermovir (PREVYMIS) is processed by the body in adults with end-stage kidney disease (ESKD), including those who are receiving intermittent haemodialysis and those who…
- Trial name
- NCT07101055
- Testing
- Letermovir 480 mg [PREVYMIS]
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Jason A Roberts
Pulmonary Hypertension
Idiopathic Pre-capillary Pulmonary Hypertension in ESKD Patients
This study investigates the prevalence and prognosis of idiopathic pre-capillary pulmonary hypertension (PH) in patients with end-stage kidney disease (ESKD).
- Trial name
- NCT02743091
- Volunteers
- 1,988 people
- Sponsor
- Toujinkai Hospital
Chronic Kidney Diseases
Assessment of T-cell Response and In-vitro Proof-of-concept of T-cell Engineering in Chronic ESKD Patients.
This is a comparative, prospective, non-interventional study to evaluate immune response in patients with chronic kidney disease.
- Trial name
- LYMPHOVIR-IRCT (NCT06474169)
- Testing
- 1 blood sample for each participant
- Where
- France
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Régional d'Orléans
End Stage Renal Disease, End Stage Renal Disease on Dialysis
Evaluation of Non-Invasive Continuous vs Intermittent BloodPressure Monitors in Maintenance Dialysis (BP Dialysis)
Prospective, single center, open label, non-randomized, post-market study of the Tablo Hemodialysis System and VitalStream Monitor in participants with End-Stage KidneyDisease undergoing In-Center Hemodialysis.
- Conditions
- End Stage Renal Disease, End Stage Renal Disease on Dialysis, Dialysis Hypotension, Dialysis Induced Hypertension
- Trial name
- NCT05540457
- Testing
- Intermittent Non-InvasiveBlood Pressure Monitor
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- The Rogosin Institute
End Stage Kidney Disease (ESKD), Hyperglycaemia
Unmasking Diabetes in Dialysis With Continuous Glucose Monitoring
This study will evaluate whether Continuous Glucose Monitoring (CGM) can identify previously unrecognized diabetes and clinically significant hyperglycemia in adults with end-stage kidney disease (ESKD) receiving hemodialysis who…
- Conditions
- End Stage Kidney Disease (ESKD), Hyperglycaemia, Diabetes
- Trial name
- NCT07880795
- Testing
- Continuous Glucose Monitoring (CGM)
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- Emory University
Secondary Hyperparathyroidism, End-stage Kidney Disease
The Effect of Increasing Dialysate Calcium on T50 in Subjects With Secondary Hyperparathyroidism and ESKD
Patients with end-stage kidney disease (ESKD) have an increased risk of cardiovascular mortality. High parathyroid hormone (PTH) from secondary hyperparathyroidism leads to increased efflux of phosphate and calcium from bone…
- Trial name
- CaT50HD (NCT06398002)
- Testing
- Dialysate calcium 1.50 mmol/L
- Volunteers
- 48 people
- Sponsor
- Iain Bressendorff
The Efficacy and Safety for Super High-flux Dialyzer in Case of Sepsis in ESKD, End Stage Kidney Disease (ESRD)
Comparing Super High-flux and High-flux Dialyzer Performance Among Hemodialysis Patient With Sepsis : a Randomized Control Trial
Comparing the efficacy of superhigh-flux dialyzer with high-flux dialyzer in ESKD patient who have sepsis to improve mortality and sepsis outcome, an open label randomized control trial.
- Conditions
- The Efficacy and Safety for Super High-flux Dialyzer in Case of Sepsis in ESKD, End Stage Kidney Disease (ESRD), Sepsis
- Trial name
- NCT06989892
- Testing
- Super High-flux dialyzer (Elisio 19HDx), High-flux dialyzer (Elisio 19H)
- Where
- Thailand
- Volunteers
- 202 people
- Sponsor
- Navamindradhiraj University
End-Stage Kidney Disease (ESKD), Non-valvular Atrial Fibrillation (NVAF)
The Safety and Effectiveness of Warfarin Vs Apixaban in Patients With NVAF/ VTE and ESKD on Dialysis
This is a retrospective study of End-Stage Kidney Disease (ESKD) patients on dialysis receiving apixaban or warfarin at Tawam Hospital [a tertiary care hospital in Al Ain, UAE].
- Conditions
- End-Stage Kidney Disease (ESKD), Non-valvular Atrial Fibrillation (NVAF), Venous Thromboembolism (VTE)
- Trial name
- WARD (NCT06606275)
- Testing
- Apixaban, Warfarin
- Where
- United Arab Emirates
- Volunteers
- 67 people
- Sponsor
- Abu Dhabi Health Services Company
Calciphylaxis
Anti-Interleukin-6 (IL6) in Calciphylaxis
Calciphylaxis is a rare but incredibly dangerous condition that causes small blood vessels in the skin to become blocked by calcium buildup and blood clots. This leads to painful skin sores (necrosis) that do not heal easily.
- Trial name
- NCT07708038
- Testing
- Tocilizumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Boston Medical Center
End-Stage Kidney Disease (ESKD)
Study of 3 Monoclonal Antibodies (REGN9933, REGN7508, and REGN9533) in Adult Participants With End-Stage Kidney Disease on Hemodialysis
This study will evaluate three Investigational Medicinal Products (IMPs) called REGN9933, REGN7508, and REGN9533. The study is focused on participants with End-Stage Kidney Disease (ESKD) treated with hemodialysis and standard…
- Trial name
- NCT07759167
- Testing
- REGN9933, REGN7508, REGN9533
- Where
- Belgium
- Volunteers
- 36 people
- Sponsor
- Regeneron Pharmaceuticals
End-Stage Kidney Disease (ESKD), Cardiovascular Disease
Cardiovascular Mortality Prediction in Maintenance Hemodialysis Patients
This prospective, single-center observational cohort study evaluates cardiovascular mortality risk in adults receiving maintenance hemodialysis.
- Conditions
- End-Stage Kidney Disease (ESKD), Cardiovascular Disease, Secondary Hyperparathyroidism (SHPT)
- Trial name
- NCT07769190
- Testing
- One-Year Serum Phosphate Target Achievement Rate, Parathyroidectomy
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Huashan Hospital
Atrial Fibrillation, End-stage Kidney Disease
Compare Apixaban and Vitamin-K Antagonists in Patients With Atrial Fibrillation (AF) and End-Stage Kidney Disease (ESKD)
The Study is an open-labeled, randomized controlled trial, phase IIIb. Its objective is to assess the safety of the factor Xa inhibitor apixaban versus the vitamin-K antagonist (VKA) phenprocoumon in patients with NVAF and ESKD…
- Trial name
- AXADIA (NCT02933697)
- Testing
- Apixaban, Phenprocoumon
- Where
- Germany
- Volunteers
- 108 people
- Sponsor
- Atrial Fibrillation Network
End-Stage Kidney Disease (ESKD), Chronic Kidney Disease (CKD)
Comparing Hemodiafiltration to Conventional Hemodialysis: Effects on Clinical and Biochemical Parameters
Chronic kidney disease may progress to end-stage renal disease, a stage in which the kidneys will no longer be able to adequately remove extra fluid and waste products from the body.
- Trial name
- NCT07662889
- Testing
- Conventional Hemodialysis, Hemodiafiltration
- Where
- Pakistan
- Volunteers
- 64 people
- Sponsor
- Services Institute of Medical Sciences, Pakistan
Secondary Hyperparathyroidism, End-stage Kidney Disease (ESKD)
Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-1
This study is to evaluate the efficacy and safety of PLS240 in patients with hemodialysis-dependent end stage kidney disease (ESKD) and secondary hyperparathyroidism (SHPT). The study consists of two phases.
- Trial name
- PATH-1 (NCT05832931)
- Testing
- PLS240, Open-Label Extension PLS240
- Where
- 68 sites in United States, Bulgaria and 4 more
- Volunteers
- 362 people
- Sponsor
- Pathalys Pharma
End-stage Kidney Disease, Kidney Disease, Chronic
Safety, Tolerability, and Feasibility of Empagliflozin Therapy in Dialysis-dependent ESKD
The purpose of this study is to find out if empagliflozin, a new diabetic medication that has been shown to be very effective in lowering the risk of heart failure, is safe and tolerated in dialysis patients.
- Conditions
- End-stage Kidney Disease, Kidney Disease, Chronic, Dialysis, Diabetic
- Trial name
- NCT05614115
- Testing
- Empagliflozin
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- University of Utah
Peripheral Artery Disease, End Stage Renal Disease on Dialysis
A Cross-Sectional Study to Assess Walking Performance in Subjects With Peripheral Artery and End Stage Kidney Disease
A cross-sectional, non-interventional study to assess walking performance, vascular function, and lower limb calcification in subjects with peripheral artery disease and end-stage kidney disease (PAD-ESKD) receiving hemodialysis.
- Trial name
- NCT04487301
- Where
- 7 sites in United States
- Volunteers
- 36 people
- Sponsor
- Sanifit Therapeutics S. A.
Chronic Kidney Disease on Hemodialysis, Physical Exercise Behavior (Liking/Aversion)
Physical Exercise in Patients With Chronic Kidney Disease in Hemodialysis (Pehedal-ESKD)
The goal of this clinical trial is to learn whether different types of exercise performed during hemodialysis are safe, well tolerated, and beneficial for adults receiving maintenance hemodialysis.
- Trial name
- Pehedal-ESKD (NCT07820514)
- Testing
- Intradialytic aerobic exercise using a cycle ergometer, Intradialytic elastic-band resistance exercise
- Where
- Italy
- Volunteers
- 312 people
- Sponsor
- Ricerca Nefrocenter
End Stage Kidney Disease (ESKD), Hypertension (HTN)
Guiding Optimal Blood Pressure Management in Peritoneal Dialysis Pilot Trial
The GOAL-BP pilot study will help determine whether a study comparing two blood pressure goals can be carried out in adults with end-stage kidney disease and high blood pressure who receive peritoneal dialysis.
- Conditions
- End Stage Kidney Disease (ESKD), Hypertension (HTN), Peritoneal Dialysis (PD)
- Trial name
- GOAL-BP (NCT07910773)
- Testing
- Target systolic blood pressure <120 mmHg., Target systolic blood pressure <140 mmHg
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- University of California, San Francisco
End Stage Kidney Disease
Duke APOL1 Research Biorepository
The Duke ApoL1 Nephropathy Biorepository aims to address needs within non-diabetic kidney failure research by utilizing existing and, when necessary, developing new infrastructure to support the consent of patients and the…
- Trial name
- DARB (NCT04160507)
- Testing
- Biorepository
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Duke University